EGFR and non-small cell lung carcinoma: However, the changes in heart rate, PR interval, and QRS duration were not statistically significant.<h4>Conclusion</h4>This study comprehensively investigates the electrocardiographic changes before and after osimertinib treatment in patients with EGFR-mutated NSCLC.